News >

Using Recurrence Risk to Tailor Treatment in HR+/HER2- Breast Cancer

Caroline Seymour
Published: Monday, Mar 25, 2019

Ruta D. Rao, MD
Ruta D. Rao, MD
In tailoring treatment to patients with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer—be it through escalated or de-escalated approaches—the key factors to consider are the patient’s risk for recurrence, how well they’re tolerating the medication, and tumor biology, said Ruta D. Rao, MD.

“The most important thing we have to take into account is the patient,” said Rao. “The patient's risk of recurrence should inform our decision on how strongly we should advocate for a longer duration of therapy. Additionally, [we need to consider] how they’re tolerating the adverse events [associated with the treatment].”

After completing 5 years of adjuvant endocrine therapy, the data are inconclusive as to whether a patient should continue on treatment or stop therapy altogether. In both the ATLAS and aTTOm trials, patients who were randomized to receive an additional 5 years of tamoxifen experienced an absolute benefit in disease-free survival (DFS) versus placebo.

Conversely, more recent data from the IDEAL trial showed no DFS benefit in patients who were randomized to receive an additional 2.5 or 5 years of letrozole. However, a subgroup analysis suggested a benefit among women with node-positive disease who completed 5 years of letrozole.

The benefit of extending therapy has to be considered alongside the adverse events (AEs) that are associated with endocrine therapy, added Rao. Among the aromatase inhibitors (AIs), those AEs include a higher fracture rate.

Beyond treatment escalation, recurrence risk and genomic classifiers are also proving useful in guiding de-escalated treatment, said Rao. As reported in the MINDACT and TAILORx trials, women categorized as low-risk according to the MammaPrint 70-gene assay and those with an Oncotype DX recurrence score of 0 to 10 and 11 to 25 can most likely receive endocrine therapy alone versus in combination with chemotherapy.

“Previously, we used to give adjuvant chemotherapy to patients who had certain characteristics based on tumor size or lymph node status,” said Rao. “What we're learning now is that it may be the tumor biology that more likely predicts the risk of recurrence.”

In an interview during the 2019 OncLive® State of the Science Summit™ on Breast Cancer, Rao, an associate professor at Rush University Medical Center, highlighted the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

OncLive: What studies have informed what is known about the optimal duration of endocrine therapy?

Rao: There are several studies that have informed our knowledge to date. Overall, what we're seeing is that 10 years of endocrine therapy may be superior to 5 years. We have a lot of different options of how to give endocrine therapy, whether it should be 10 years of tamoxifen, 5 years of tamoxifen followed by 5 years of an AI, or other combinations of the 2 therapies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication